Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations
Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations |
| [29-July-2026] |
VANCOUVER, BC and LAS VEGAS, July 29, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (FSE: SO6) (OTCQB: HYDTF), a digital health platform connecting healthcare providers, pharmacies and patients across the United States, today provided an update on its peptide healthcare platform following the recent recommendations of the U.S. Food and Drug Administration's ("FDA") Pharmacy Compounding Advisory Committee ("PCAC").
During its July 23–24, 2026 meeting, the PCAC recommended that six peptide-related bulk drug substances—BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon—be considered for inclusion on the FDA's Section 503A Bulks List. These recommendations are advisory only, do not constitute FDA approval of any substance or finished drug product, and remain subject to the FDA's rulemaking process. Management considers these recommendations material because peptide-based therapies already represent a significant component of Hydreight's existing business. Through its physician-supervised healthcare platform, the Company currently supports multiple peptide-based treatment categories and has made substantial investments in physician infrastructure, pharmacy relationships, clinical protocols and technology supporting peptide-based care. "The recent PCAC recommendations are meaningful because they relate to a therapeutic category where Hydreight already operates today," said Shane Madden, Chief Executive Officer of Hydreight. "We've spent years building the physician, pharmacy and technology infrastructure supporting peptide-based healthcare. The recommendations don't change our strategy—they reinforce why we've been investing in this category for years while continuing to focus on compliant, physician-supervised care." Peptide-Based Medicine is Already an Established Part of Hydreight's Business The Company currently supports multiple physician-supervised peptide-based treatment categories through its nationwide physician, pharmacy and technology platform, including GLP-1 therapies, Sermorelin and Ipamorelin. These peptide-based therapies form part of Hydreight's broader personalized healthcare platform, which also includes hormone optimization, NAD+ therapies, IV wellness, sexual health, hair restoration and other physician-supervised healthcare programs. Platform Expansion Driven by Existing Peptide Business Hydreight's peptide healthcare platform has been under development since 2019 and reflects the Company's long-term strategy of building a nationwide physician-enabled healthcare infrastructure supporting compliant personalized healthcare. Since 2019, Hydreight has continued investing in its physician, pharmacy and technology infrastructure with the objective of building a scalable platform capable of supporting physician-supervised personalized healthcare across the United States. Today, the Company's healthcare ecosystem includes:
The investments described above were undertaken as part of Hydreight's long-term platform strategy and were not initiated in response to the recent PCAC recommendations. This infrastructure was developed well before the recent PCAC recommendations and supports peptide-based therapies currently available through the Company's platform. It also provides the operational foundation to evaluate additional physician-supervised treatment categories should future regulatory pathways permit their introduction, subject to applicable legal, clinical and regulatory requirements. As part of these investments, Hydreight has completed medical policies, provider protocols and VSDHOne technology workflows supporting currently available physician-supervised peptide-based treatment categories, while also expanding pharmacy relationships and fulfillment capacity supporting compliant nationwide healthcare delivery. Clinical, Pharmacy and Technology Infrastructure As peptide-based healthcare has become a larger component of Hydreight's business, the Company has continued investing in infrastructure supporting physician-supervised treatment categories. Completed initiatives include:
These initiatives support treatment categories currently available through the platform while also providing operational readiness should additional physician-supervised therapies become legally available in the future. Existing Peptide Strategy Hydreight's peptide healthcare platform includes physician-supervised GLP-1 therapies, Sermorelin, Ipamorelin and other peptide-based treatment categories delivered through the Company's nationwide physician, pharmacy and technology infrastructure. The Company has continued expanding this platform through investments in clinical protocols, provider workflows, pharmacy relationships and VSDHOne technology, providing the operational foundation to support compliant physician-supervised peptide-based healthcare. Hydreight's strategy extends beyond its currently available treatment categories. Earlier this year, the Company announced its strategic investment in Insu Therapeutics Inc., a biotechnology company developing proprietary buccal drug delivery technology for peptide and biologic medicines. Together, Hydreight's existing peptide-based treatment categories, nationwide physician and pharmacy infrastructure, VSDHOne platform and investment in Insu Therapeutics reflect the Company's long-term strategy of building an integrated healthcare platform supporting physician-supervised personalized medicine. FDA Advisory Committee Recommendations During its July 23–24 meeting, the PCAC recommended six peptide-related bulk substances for potential inclusion on the Section 503A Bulks List:
The committee did not recommend Emideltide (DSIP). The recommendations relate solely to potential inclusion on the Section 503A Bulks List and do not constitute FDA approval. Hydreight notes that any future implementation of products involving these substances would remain subject to applicable FDA rulemaking, federal and state regulations, physician oversight, pharmacy participation and product-specific legal and clinical review. Looking Ahead Hydreight will continue executing its long-term strategy of expanding its physician, pharmacy and technology infrastructure supporting currently available treatment categories while evaluating additional physician-supervised therapies in accordance with applicable legal, clinical and regulatory requirements. On behalf of the Board of Directors Shane Madden About Hydreight Technologies Inc. About VSDHOne - Direct to Consumer Platform Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Information Forward‑looking information is based on management's expectations, estimates and assumptions as of the date hereof, including assumptions regarding: continued partner adoption, stable regulatory regimes applicable to telehealth and pharmacy operations in the United States, availability of capital, and general economic conditions. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company's shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
SOURCE Hydreight Technologies Inc. | ||
Company Codes: Frankfurt:SO6,OTC-BB:HYDTF,OTC-PINK:HYDTF,OTC-QB:HYDTF,TorontoVE:NURS |
View original content to download multimedia:
